Fierce Pharma Biopharma News & Insights
Nov 4, 2024 · Fierce Pharma delivers breaking news and analysis about drug companies, the FDA and the broader pharma industry, including manufacturing, marketing and finance.
Pharma | Fierce Pharma
Oct 14, 2024 · GSK breaks up with BIO for 2025. The company opted not to renew its membership following an annual review of its trade group associations, a spokesperson said. Zoey Becker Nov 8, 2024 4:51pm.
Top 20 Pharmaceutical Companies by Revenue 2021 | FiercePharma
The pharma industry quickly took center stage when COVID-19 caught the world off guard early last year. As 2020 progressed, drugmakers battled the coronavirus on one hand and on the other ...
Fierce 50 | Fierce Pharma
Jan 22, 2024 · A closer look at the Fierce 50. In this week's episode of "The Top Line," we will dive into the annual Fierce 50 special report. Ayla Ellison Sep 13, 2024 9:51am. Connect. The Team.
Top 20 pharma companies by 2023 revenue - Fierce Pharma
J&J was No. 1 in 2023 by a comfortable margin over No. 2 Roche, which raked in sales of $58.7 billion Swiss francs ($67 billion) last year. J&J’s big lead is especially noteworthy considering ...
Asia - Fierce Pharma
5 days ago · AstraZeneca CEO defends $80B revenue target amid China probes. Concerns over AZ’s large China business escalated in the past few days after senior executives were detained as part of an ...
Big Pharma Companies Ranked by Revenue 2022 - Fierce Pharma
Apr 18, 2023 · While a few companies continued to reap huge profits from COVID products in 2022, others benefited from a return to normalized business operations.
About Us - Fierce Pharma
About Us. Biopharma is a fast-growing world where big ideas come along daily. Our readers rely on Fierce Pharma for the latest news, analysis and data on drugs and the companies that make them ...
The top 10 most profitable pharma companies in 2021
The six largest drugmakers by 2021 revenue—J&J, Pfizer, Roche, AbbVie, Novartis and Merck & Co.—all made the top profit list but in quite a different order.
Biotech - Fierce Pharma
Oct 29, 2024 · Amgen, AZ's Tezspire excels in phase 3 rhinosinusitis trial. A phase 3 study has shown that AZ and Amgen's Tezspire worked in patients with severe chronic rhinosinusitis with nasal polyps. Kevin ...